Kymera Stock Soars on Breakthrough Eczema Drug Results
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.
/ 474 items
#Healthcare↓
Ocular Therapeutix Stock Jumps 27% on Accelerated Drug Approval Plans
Ocular Therapeutix (OCUL) shares surge 27% after announcing plans to fast-track FDA submission for Axpaxli, a promising new treatment for wet age-related macular degeneration affecting millions.
Dyne Therapeutics Hits Milestone with Promising Duchenne Drug, Eyes 2026 Approval
Dyne Therapeutics' experimental DMD treatment shows strong results in late-stage trial, potentially offering more effective alternative to current controversial therapies with 10x higher dystrophin levels.
Anito-cel Shows High Efficacy and Impressive Two-Year Survival Rates in Relapsed/Refractory Multiple Myeloma
New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.
Higher Dose Sickle Cell Pill Shows Improved Results, But Experts Urge Caution
Fulcrum's (FULC) experimental oral treatment for sickle cell disease demonstrates stronger fetal hemoglobin increases at 20mg dose, though researchers emphasize it's not a cure for the genetic disorder.
CooperCompanies Launches Strategic Review and Names New Board Chair
CooperCompanies initiates strategic review exploring partnerships and divestitures while appointing Colleen Jay as new board chair. Q4 revenue up 5% to $1.07B.